Cutiss
Cutiss is a life science company that engages in regenerative medicine production, skin tissue engineering, and curated therapy solutions.
About Cutiss
Cutiss AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin is expected to result in a minimally scarring outcome after transplantation. denovoSkin received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Company Facts
- Headquarters
- Z├╝rich
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- late_stage_venture
- Total Funding
- $94,580,943
- Last Funding Type
- series_c
- Last Funding Date
- 2025-09-10
- Website
- cutiss.swiss
Industries & Categories
Beauty, Biotechnology, Cosmetics, Health Care
Social Links
Canonical: https://fsome.com/organization/cutiss-98739 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.